Educational Objectives

At the conclusion of these educational activities, participants will be expected to be able to:

• Describe the rationale for, and the recommendations of, current guidelines related to VTE prophylaxis.
• Critically evaluate their adherence to guidelines as it relates to VTE prophylaxis, and apply a greater appreciation of the rigorous use of VTE prophylaxis measures in appropriate case scenarios.

Intended Audience

This activity has been designed to meet the educational needs of physicians of multiple specialties who are in a position to be responsible for patients at risk for venous thromboembolism in the medical setting.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Indiana University School of Medicine, Twine Clinical LLC, and the North American Thrombosis Forum (NATF). Indiana University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Indiana University School of Medicine designates these educational activities for a maximum of 1.0 or 2.0 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

• Prevention of VTE: A National Healthcare Priority: 2.0 AMA PRA Category 1 Credits^TM
• Pregnancy-Related Thrombosis 1.0 AMA PRA Category 1 Credits^TM
• Thrombosis in Cancer: 1.0 AMA PRA Category 1 Credits^TM
• VTE: Difficult Treatment Scenarios: 1.0 AMA PRA Category 1 Credits^TM

Statement of Responsibility

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions or views expressed in this CME activity are those of the presenters and do not necessarily reflect the opinions or recommendations of Indiana University School of Medicine, Twine Clinical LLC, NATF or the commercial supporter(s). Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.

Disclosure of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by the Indiana University School of Medicine must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, and planning committee members participating in an Indiana University School of Medicine-sponsored activity are required to disclose any relevant financial interest or relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Planning Committee members Ian Donovan, PhD & Daniel Wray, MS, MBA, of Twine Clinical, as well as Ilene Sussman, PhD, of the North America Thrombosis Forum, have no relevant financial relationships to disclose.

Andra H. James, MD, MPH, has no relevant financial relationships to disclose.
Robert Pendleton, MD, has no relevant financial relationships to disclose.
Scott C. Woller, MD, FACP, has no relevant financial relationships to disclose.
Neil A. Zakai, MD, MSc, has no relevant financial relationships to disclose.
Agnes Y. Y. Lee, MD, MSc, FRCPC, reported the following: Eisai Pharmaceuticals, Leo Pharma, Boehringer Ingelheim, sanofi-aventis and Pfizer

Sponsors

Supporters